Clinical trial
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
NCT00274144 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00274144 |
|---|---|
| Title | Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism |
| Official title | Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Coronary Arteriosclerosis |
| Intervention type | Drug |
| Interventions | telmisartan 40 mg, placebo 40 mg |
| Enrollment | 42 |
| Start date | Dec 1, 2001 |
| Primary completion | Mar 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Jan 10, 2006 |
| Last update posted | Nov 1, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: